Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29465769 | 1.00 | ALDH1A1 (0.33) | ALDH1A1KCNJ1 | |
| SCHEMBL14775276 | 0.82 | — | — | |
| SCHEMBL26920416 | 0.80 | SGK1 (0.33) | ALDH1A1 | |
| SCHEMBL29844672 | 0.78 | KCNJ1 (0.46) | ALDH1A1KCNJ1 | |
| SCHEMBL22678487 | 0.78 | KCNJ1 (0.46) | ALDH1A1KCNJ1 | |
| SCHEMBL29956623 | 0.78 | CDK2 (0.35) | ALDH1A1 | |
| SCHEMBL30901440 | 0.77 | PDCD1 (0.45) | — | |
| SCHEMBL21290658 | 0.77 | PDCD1 (0.45) | — | |
| SCHEMBL23214420 | 0.74 | ALDH1A1 (0.39) | ALDH1A1KCNJ1 | |
| SCHEMBL29955836 | 0.74 | GRM5 (0.36) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642773-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-11-05 | — | — | EP | disclosed |
| US-20250270195-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-08-28 | — | — | US | disclosed |
| US-12338233-B2 | PD-1/Pd-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250195511-A1 | INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | MERCK SHARP & DOHME LLC (US) | 2025-06-19 | — | — | US | disclosed |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| EP-4506035-A2 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20250034170-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2025-01-30 | — | — | US | disclosed |
| US-12138263-B2 | Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-12084447-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| EP-3768668-B1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20100292210-A1 | Novel Compounds for A-Beta-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| WO-2010132015-A1 | NEW COMPOUNDS MODULATING GAMMA-SECRETASE AND THEIR USE IN THE TREATMENT OF ALPHA BETA RELATED PATHOLOGIES, SUCH AS ALZHEIMER'S DISEASE | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010016005-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010016005-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| US-6982268-B2 | Substituted imidazolylmethyl pyridine and pyrazine derivatives GABAA receptor ligands | NEUROGEN CORPORATION (US) | 2006-01-03 | — | — | US | disclosed |
| EP-1501825-A2 | SUBSTITUTED IMIDAZOLYLMETHYL PYRIDINE AND PYRAZINE DERIVATIVES: GABA A RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2004041809-A2 | SUBSTITUTED IMIDAZOLYLMETHYL PYRIDINE AND PYRAZINE DERIVATIVES AND THEIR USE AS GABAA RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20030220348-A1 | Substituted imidazolylmethyl pyridine and pyrazine deriviatives GABAa receptor ligands | NEUROGEN CORPORATION | 2003-11-27 | — | — | US | disclosed |
| US-20030220348-A1 | Substituted imidazolylmethyl pyridine and pyrazine deriviatives GABAa receptor ligands | NEUROGEN CORPORATION | 2003-11-27 | — | — | US | disclosed |
| US-20030220348-A1 | Substituted imidazolylmethyl pyridine and pyrazine deriviatives GABAa receptor ligands | NEUROGEN CORPORATION | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034170-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | GBA1, GAA, GBA2 | ALDH1A1 1971/4885KCNJ1 2901/4885 |
| US-20030220348-A1 | Substituted imidazolylmethyl pyridine and pyrazine deriviatives GABAa receptor ligands | GABRP, GABBR1, GABRA1 | ALDH1A1 512/4885KCNJ1 798/4885 |
| US-20250195511-A1 | INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | NLRP3, FABP3, NOD1 | ALDH1A1 3907/4885KCNJ1 3694/4885 |
| US-12338233-B2 | PD-1/Pd-L1 inhibitors | PDCD1, CD274, PDCD1LG2 | ALDH1A1 115/4885KCNJ1 4228/4885 |
| US-12084447-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPN22, PTPN1 | ALDH1A1 3280/4885KCNJ1 4592/4885 |
| US-20250270195-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | ALDH1A1 115/4885KCNJ1 4228/4885 |
| US-20100292210-A1 | Novel Compounds for A-Beta-Related Pathologies | BACE1, APP, BACE2 | ALDH1A1 2384/4885KCNJ1 4094/4885 |
| US-12138263-B2 | Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof | PTPN2, PTPN5, PTPRJ | ALDH1A1 2974/4885KCNJ1 4074/4885 |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPN22, PTPN1 | ALDH1A1 3280/4885KCNJ1 4592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.